Dusseldorf, Germany, November 17, 2026 - Priavoid GmbH (“Priavoid”) today announced topline results from its randomized, double-blind, placebo-controlled Phase 2 trial (PRImus-AD, NCT06182085), evaluating its lead candidate PRI-002 in patients with early Alzheimer's disease (AD). The study met its primary safety endpoint, with PRI-002 demonstrating a favorable safety and tolerability profile while the primary efficacy endpoint, measured by change from baseline in CDR-SB at Week 48, was not met. The topline results showed promising signals across key measures of cognition and daily functioning, with numerical difference favoring PRI-002. These trends became more pronounced at week 72, reaching statistical significance in the per protocol population in the ADAS-Cog. The overall findings, including preliminary biomarker analysis, support further clinical evaluation of PRI-002, an oral all-D-peptide compound designed to disassemble neurotoxic amyloid-beta (Aβ) oligomers.
The topline results were presented today by Prof. Dr. Oliver Peters, Chief Medical Officer of Priavoid, during an oral presentation at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, USA. The company plans to present the full dataset, including additional safety, clinical efficacy and biomarker analyses, at scientific conferences in 2027.
“These initial results represent an important milestone in our clinical development program and provide valuable insights into PRI-002’s safety and clinical activity,” said Philipp Bürling, Chief Executive Officer at Priavoid GmbH. “We are particularly encouraged by the favorable safety and tolerability profile and the positive clinical signals observed in cognitive and functional measures. Together with the preliminary biomarker findings, these results also provide encouraging initial support for our first-in-class detangler approach and its broader therapeutic potential. As we continue our comprehensive analyses to determine the Next steps for PRI-002, I would like to thank SPRIND for funding this important study and our investors for their continued trust and support.”
PRImus-AD Topline Results
The study enrolled 304 patients with MCI Capital or mild dementia due to AD, randomized 1:1:1 to receive oral PRI-002 at 300 mg or 600 mg daily, or placebo. The trial followed a common-close design, with treatment durations ranging from 48 to 96 weeks, allowing earlier-enrolled patients to receive treatment for longer periods. The study ended for all patients when the last patient reached 48 weeks of treatment.
Safety and tolerability
Clinical efficacy
The efficacy analysis was conducted for both the modified intention-to-treat (mITT) population and the per protocol population. Data from both PRI-002 dose groups (300 mg and 600 mg) was pooled for analysis due to highly overlapping plasma concentrations. Overall results showed encouraging signals across measures of cognition and daily functioning:
“We are encouraged by the clinical signals observed in PRImus-AD, particularly the findings favoring PRI-002 in measures of cognition and daily functioning,” said Prof. Dr. Oliver Peters, Chief Medical Officer of Priavoid. “PRI-002 has demonstrated a favorable safety and tolerability profile, combined with a convenient oral treatment regimen. For people living with Alzheimer's disease, a treatment that could slow cognitive and functional decline while fitting into their daily lives would contribute to quality of life. We look forward to further exploring these findings and defining the Next steps in PRI-002’s clinical development.”
Biomarker analyses
“The PRImus-AD results represent an important milestone and the culmination of years of fundamental research conducted at Heinrich Heine University Düsseldorf and Forschungszentrum Jülich. What began as a scientific concept to directly Target and disassemble neurotoxic amyloid-beta oligomers has now progressed to clinical evaluation, with encouraging initial findings,” said Prof. Dr. Dieter Willbold, Co-Founder and Chief Science Officer of Priavoid. “The preliminary biomarker findings provide further support for our approach of targeting neurotoxic amyloid-beta oligomers. While we continue our analysis, these initial observations are consistent with PRI-002’s proposed biological activity and strengthen our confidence in the therapeutic potential of our detangler platform.”
The encouraging clinical signals, favorable safety profile and preliminary biomarker findings provide a rationale for the ongoing clinical development of PRI-002 as a potentially disease-modifying oral treatment for Alzheimer's disease. Priavoid is conducting comprehensive analyses of the PRImus-AD dataset, including additional assessments of clinical efficacy, safety, Alzheimer's disease-related biomarkers and brain volumetric measurements. The full dataset is expected to be presented at scientific conferences in 2027, with the findings informing the Next steps in clinical development, including the potential design of a subsequent study.
The topline data presentation can be accessed here.
About the PRImus-AD Phase 2 trial
PRImus-AD (NCT06182085) is a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating the safety, tolerability and efficacy of PRI-002 in patients with mild cognitive impairment ( MCI Capital ) or mild dementia due to Alzheimer's disease. The study enrolled 304 participants aged 55-80 years across 38 clinical sites in six European countries. Participants were randomized 1:1:1 to receive oral PRI-002 at 300 mg or 600 mg daily, or placebo, for 48-96 weeks. Under the common-close design, the study concluded when the last enrolled participant completed the Week 48 visit, allowing earlier participants to receive treatment for longer periods. The primary endpoints included safety and tolerability, assessed through adverse events, serious adverse events and amyloid-related imaging abnormalities (ARIA), and efficacy, measured by change from baseline in CDR-SB at Week 48. Secondary endpoints included cognitive performance, assessed by ADAS-Cog13, activities of daily living, assessed by ADCS-ADL, and additional cognitive measures. Biomarker assessments included Alzheimer's disease-related markers in plasma and cerebrospinal fluid, alongside brain volumetric analyses.
PRInnovation GmbH, sponsor of the PRImus-AD trial, is an affiliate of The Federal Agency for Breakthrough Innovation – SPRIND GmbH.
About PRI-002
PRI-002 is a novel, orally available all-D-peptide candidate based on Priavoid’s proprietary detangler platform. The compound is designed to Target Aβ oligomers, a key driver associated with AD. In contrast to currently available treatments, PRI-002 is designed to bind neurotoxic Aβ oligomers and promote their disassembly into non-toxic monomers. Through its distinct mode of Action , PRI-002 is designed to intervene early in the AD pathway by addressing neurotoxicity at its source while avoiding treatment-mediated immune responses that can trigger serious side effects including ARIA.
About Priavoid
Priavoid’s novel class of orally available all-D-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. Our lead program, PRI-002, has completed a Phase 2 clinical trial in Alzheimer’s disease, demonstrating a favorable safety profile and encouraging initial efficacy signals that warrant further clinical investigation. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical Benefit for patients.
Priavoid GmbH is a spin-off from Heinrich Heine University Düsseldorf and Forschungszentrum Jülich, with Prof. em. Dr. Dr. h.c. Detlev Riesner serving as Seedinvestor and Chairman of the Supervisory Board.
Contacts:
Priavoid GmbH Düsseldorf
Email: media@priavoid.com
Media Requests
Trophic Communications
Anja Heuer and Marie Weickert, PhD
Phone: +49 151 106 199 05
Email: priavoid@trophic.eu
Attachment